Industry Wire 236

January 3, 2025 Viktor Zarev 0 min read
  1. NHS flu hospitalizations quadruple.
  2. PA-targeted doctoral programs booming, but inconsistent.
  3. Family sues Amazon One Medical after fatal telehealth advice.
  4. HHS commits $306M to Avian Flu monitoring and preparedness.
  5. Indianapolis’s Community Health Network paying $152M for kickbacks and false claims.
  6. Ransomware costs U.S. healthcare orgs $1.9M in daily downtime. 
  7. Woman crashes through NJ hospital ED doors, drives down hallway.
  8. States reduce certificate of need laws to increase care capacity.
  9. New Massachusetts bill bolsters healthcare industry oversight.
  10. Ascension cyberattack exposes 5.6M patients’ data.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Pharmaceuticals September 10, 2026

Novo, Novartis, and How Two Trials Cast Doubt on CVD Biomarkers September 10, 2026

Cardiology just took back-to-back blows to two of its most promising prevention strategies. One drug for lowering lipoprotein(a) and another targeting interleukin-6 both failed in major trials, even as fresh data reaffirms just how much those factors matter.

Surgeries & Interventions September 3, 2026

A Tale of Two Studies and the Importance of Patient Selection September 3, 2026

Two recent studies are forcing an important conversation in cardiology – some of the field's most common procedures may not be as clearly beneficial as open-label data originally suggests.

Cardiology Pharmaceuticals August 31, 2026

The Full Picture Clarifies Aficamten’s Impact on nHCM August 31, 2026

We are inching closer to a treatment for nonobstructive hypertrophic cardiomyopathy after Cytokinetics presented the full results from the ACACIA-HCM trial, showing that its cardiac myosin inhibitor, MYQORZO (aficamten), meaningfully improves how nHCM patients feel and function.